A phase I clinical trial for malignant ascites is planned to initiate in China this year.
Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercialising biologic therapies, with a focus on oncology and autoimmune diseases.
Clover is utilizing its proprietary Trimer-Tag© technology platform to develop novel biologics targeting trimerization-dependent pathways.
Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.
Trimer-Tag© is a drug development platform which allows the production of novel, covalently-trimerized fusion proteins.
Many major disease targets are trimerization-dependent such as the tumor necrosis factor superfamily (involved in extrinsic apoptosis, immune co-stimulation and inflammation) as well as enveloped RNA virus antigens responsible for entry into host cells.
Clover is using Trimer-Tag© technology to create trimerized fusion proteins that are able to effectively target these previously undruggable pathways.
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026